probenecid (Hospital General Universitario Gregorio Marañón)

ALME23 is a code name used in research settings to refer to probenecid, a well-established organic anion transporter (OAT) inhibitor clinically approved for the treatment of gout and hyperuricemia. Probenecid acts by inhibiting renal transporters, primarily OAT1 and OAT3, which are responsible for the tubular uptake and secretion of various organic anions. In the context of oncology and nephrology, researchers from the Hospital General Universitario Gregorio Marañón are investigating probenecid (under the code ALME23) as a potential nephroprotective agent to prevent cisplatin-induced acute kidney injury (AKI). By blocking OAT-mediated cellular uptake of cisplatin metabolites in proximal tubular cells, ALME23 aims to reduce intracellular accumulation, apoptosis, and inflammatory damage in the kidneys without compromising the systemic chemotherapeutic efficacy of cisplatin.

Brand names

BenemidProbalan

Other names

4-(dipropylsulfamoyl)benzoic acid